Review the clinical trials taking place involving ischemic heart disease.
Study title: ABSORB
A clinical evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of subjects of de novo Native Coronary Artery Lesions.
Principal investigator: Dr. Jerome Williams, Jr.
What is the purpose of the study?
The purpose of the pivotal trial is to support the US pre-market approval (PMA) of Absorb BVS. ABSORB will evaluate the safety and effectiveness of the Absorb BVS System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease caused by up to two de nova native coronary artery lesions in separate epicardial vessels.
Who is eligible?
Patients who qualify for a percutaneous coronary artery revascularization procedure and meet all the inclusion and none of the exclusion criteria required by the study.
For more information, contact:
Dr. Jerome Williams. Jr
Link to the current ClinicalTrials.gov record »